Finance

Beta
Lists
CMPS:NASDAQ
Compass Pathways PLC
$12.69
-4.80%
(-0.64) 1D
$12.54
-1.18% (-0.15)
After hours
Closed: Jun 3, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPS...
Open
$13.36
High
$13.36
Low
$12.50
Mkt. cap
1.71B
Avg. vol.
4.64M
Volume
3.19M
52-wk high
$14.76
52-wk low
$2.25
EPS
-$2.00
Beta
2.50
Shares outstanding
134.95M
No. of employees
156
Open
$13.36
High
$13.36
Low
$12.50
Mkt. cap
1.71B
Avg. vol.
4.64M
Volume
3.19M
52-wk high
$14.76
52-wk low
$2.25
EPS
-$2.00
Beta
2.50
Shares outstanding
134.95M
No. of employees
156
Analyst outlook
Analyst Ratings
Based on 12 analysts giving stock ratings to CMPS in the past 3 months
Strong Buy
Buy
12
Hold
0
Sell
0
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CMPS in the last 3 months.
Highest
Current $12.69
$70.00 (+451.62%)
Average
$23.50 (+85.19%)
Lowest
$14.00 (+10.32%)
News stories
From sources across the web
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC
CEO-
Employees156
FoundedJun 13, 2016
Headquarters-
SectorBiotechnology
Websitecompasspathways.com
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.30 / -$0.32
+4.76%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
26.04M
23.40M
42.82M
24.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.61M
13.21M
16.05M
16.42M
Operating expense
38.65M
36.61M
58.86M
40.43M
Total operating expenses
38.65M
36.61M
58.86M
40.43M
Operating income
-38.65M
-36.61M
-58.86M
-40.43M
Other non operating income
-2.72M
-100.94M
-37.79M
131.40M
EBT including unusual items
-38.27M
-137.95M
-96.61M
91.19M
EBT excluding unusual items
-38.27M
-137.95M
-96.61M
91.19M
Income tax expense
137.00K
-230.00K
-2.73M
-11.00K
Effective tax rate
-0.36%
0.17%
2.83%
-0.01%
Other operating expenses
-
-
-
-
Net income
-38.40M
-137.72M
-93.88M
91.20M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-0.38
-0.61
-0.30
Interest and investment income
1.90M
1.59M
1.31M
2.42M
Interest expense
-1.15M
-1.10M
-1.14M
-1.46M
Net interest expenses
747.00K
483.00K
173.00K
954.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.49M
-36.60M
-58.86M
-40.37M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer